Organ Transplants

Candidates include end-stage kidney, liver, heart, or lung failure (and select pancreas/combined indications) after multidisciplinary evaluation. Options cover living-donor (where lawful) and deceased-donor programs under THOTA/NOTTO. India offers JCI/NABH-accredited centers, modern ICUs, and costs several-fold lower than US/Europe—coordinated end-to-end by MediHeal International.

• Kidney: ESRD (CKD stage 5) on dialysis or eGFR ≤15 with symptoms; selected metabolic diseases; pediatric ESRD.
• Liver: Acute liver failure or decompensated cirrhosis (ascites/variceal bleed/encephalopathy/jaundice); HCC within listing criteria; pediatric indications (e.g., biliary atresia).
• Heart: Advanced heart failure (NYHA III–IV) refractory to guideline-directed therapy, low LVEF, VAD/inotrope dependence or recurrent admissions.
• Lung: End-stage ILD/IPF, severe COPD/emphysema, CF/bronchiectasis, pulmonary hypertension with oxygen dependence despite maximal therapy.
• Pancreas/combined: Type 1 diabetes with brittle control or hypoglycemia unawareness (SKP/PAK in select centers).
• General: Must clear multidisciplinary evaluation and lack absolute contraindications (uncontrolled infection/malignancy outside criteria, irreversible comorbidity, inability to adhere to follow-up).

• JCI/NABH-accredited centers with transplant ICUs, infection control, and experienced multidisciplinary teams.
• Costs are several-fold lower than Western systems with transparent inclusions and defined pathways.
• International desks streamline opinions, itemized quotes, authorization scheduling, visas, and logistics.

• Case triage and center matching by organ type, urgency, donor availability, and travel constraints.
• Transparent, itemized quotes (donor/recipient work-ups, ICU day caps, immunosuppression brands, contingency costs).
• Logistics: visas (recipient & eligible living donor), airport pickup, accommodation, interpreters, and tele-follow-ups.

• Kidney Transplant— Living-donor (near relative only under THOTA) or deceased-donor; ABO/HLA/crossmatch compatibility; typical stay ~10–14 days if uncomplicated.
• Liver Transplant— Living-donor (right lobe/left lateral) or deceased-donor; MELD-based priority; ICU ~3–7 days; total stay ~2–3 weeks when stable.
• Heart Transplant— For advanced refractory heart failure; may require VAD/ECMO bridge; intensive rehab and strict infection prophylaxis.
• Lung Transplant— Single or bilateral deceased-donor; indications include end-stage ILD/COPD; aggressive infection control and prolonged follow-up.
• Pancreas / Combined— Pancreas alone (select centers) or simultaneous kidney-pancreas for T1D with ESRD; lifelong metabolic and immunosuppression monitoring.

1. Pre-arrival

   • Share complete records: imaging, labs, echo/angiography (as relevant), dialysis or decompensation history, and medications.
   • Receive written plan: eligibility, required authorizations, donor/recipient work-ups, estimated ICU/ward days, itemized costs.

2. Pre-op & Admission

   • Comprehensive evaluation for recipient (and living donor where applicable): ABO/HLA, crossmatch, imaging, psychosocial & nutritional assessment.
   • Authorization committee scheduling per THOTA; medical visas for recipient and donor; FRRO/FRO registration if required.

3. Surgery & Early Recovery

   • Transplant in specialized OTs with intra-op monitoring; transfer to transplant ICU with strict infection control.
   • Early graft function surveillance, immunosuppression initiation, and step-down planning.

4. Rehabilitation & Follow-up

   • Discharge education on medications, infection precautions, diet, and clinic schedule.
   • Tele-reviews, digital records, and handover to home-country physicians; fit-to-fly documentation.

1. In-hospital

   Commonly 7–21 days depending on organ, ICU needs, and complications.

2. Early recovery

   4–8 weeks for basic activities with frequent labs and clinic follow-up.

3. Long-term

   Lifelong immunosuppression, infection-prevention, vaccinations, and scheduled surveillance.

• Life-saving therapy with improved survival versus end-stage organ failure on medical treatment alone.
• Marked symptom relief and functional gains (e.g., freedom from dialysis; reversal of hepatic decompensation; improved exercise capacity/oxygenation).
• Structured programs with defined protocols, ICU readiness, and coordinated international logistics reduce delays and uncertainty.

• Request itemized quotes with donor/recipient work-ups, ICU day caps, immunosuppression brands, complication contingencies, and extension rates.

• Medical visas for recipient and (if applicable) living donor; multiple entries commonly allowed for treatment duration.
• FRRO/FRO registration may be required; deceased-donor allocation to foreigners occurs only when no Indian recipient is in need nationwide at that time.

• Optimize organ-specific health (cardiac/pulmonary/renal), nutrition, and treat active infections; complete recommended vaccinations.
• Compile full records, imaging, and medication lists; arrange caregiver support and nearby lodging for 6–8 weeks (liver) or as advised.

• Medication adherence and regular labs for drug-level/organ function monitoring.
• Infection-prevention routines, diet & lifestyle counseling, and vaccination scheduling.
• Planned tele-follow-ups and coordination with home-country physicians for continuity.